ORGANOVO Forum: Community User: Trader_100

Denke sehr bald greifen wir die 2,50 an und dann Richtung 3 Euro

Sieht gut aus

Ich kauf hier auch nochmal nach.. Könnte wieder auf 3 hoch..

Sehr gut. Klingt gut. Und langsam wird es hier was voller in der Runde. Schön!

Organovo Holdings, Inc. (ONVO) New Analyst Ratings By Brenton Akerman / in Broker Ratings / on Friday, 04 Mar 2016 12:50 PM / 0 Comments Market analysts have recently updated their ratings and price targets on shares of Organovo Holdings, Inc. (ONVO). The latest reports which are currently in issue on Friday 4th of March state 1 analyst has a rating of “strong buy”, 1 analysts “buy”, 1 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”. Most recent broker ratings and price targets 02/10/2016 – Organovo Holdings, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 3 price target on the stock. 10/12/2015 – Organovo Holdings, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 4 price target on the stock. 08/11/2015 – Organovo Holdings, Inc. was downgraded to “hold” by analysts at Cantor Fitzgerald. They now have a USD 3.5 price target on the stock. 02/11/2015 – Organovo Holdings, Inc. had its “market perform” rating reiterated by analysts at JMP Securities. 02/18/2014 – Thomson Reuters/Verus began new coverage on Organovo Holdings, Inc. giving the company a “hold” rating. Organovo Holdings, Inc. has a 50 day moving average of 2.04 and a 200 day moving average of 2.70. The stock’s market capitalization is 212.55M, it has a 52-week low of 1.60 and a 52-week high of 5.82. The share price of the company (ONVO) was up +2.68% during the last trading session, with a high of 2.41 and the volume of Organovo Holdings, Inc. shares traded was 920740. Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter. RECOMMENDED POSTS Changes To Broker Targets On Primero Mining Corp (NYSE:PPP) Recently some investment brokers have made changes to their outstanding price targets on shares of Primero... PPL Corporation (NYSE:PPL) Updated Price Targets Recently analysts working for a variety of stock market brokerages have changed their consensus ratings... Peregrine Pharmaceuticals Inc. (PPHM) Broker Target Changes At the moment 3 analysts are watching Peregrine Pharmaceuticals Inc. (PPHM), 1 rate it “Buy”, 1 “Outperform”,... Changes To Broker Targets On PPG Industries, Inc. (NYSE:PPG) Recently some investment brokers have made changes to their outstanding price targets on shares of PPG... Free Email Newsletter Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: RECENT POSTS Changes To Broker Targets On Primero Mining Corp (NYSE:PPP) PPL Corporation (NYSE:PPL) Updated Price Targets Peregrine Pharmaceuticals Inc. (PPHM) Broker Target Changes Changes To Broker Targets On PPG Industries, Inc. (NYSE:PPG) Pilgrim’s Pride Corporation (NASDAQ:PPC) New Analyst Ratings

Schade verpasst

Max h wie viel Stück hast ?

Hab's storniert Jetzt Frankfurt

Da ist aber kein Volumen in München.. sicher?

Bin gerade über München eingestiegen

Danke schonmal. :)

Ok..

Van Halen leg nach

80 patente in Prüfung Leute die geht ruck zuck hoch die verschnauft nur noch gerade einsteigen bitte

Beide Kursziele um die 6 Euro

Und noch ein anderer Analyst